SEC Form 4 · accession 0001567619-18-007048

Loxo Oncology, Inc. · LOXO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Jennifer Burstein

Officer — Senior VP of Finance

Period of report

Nov 26, 2018

Accepted (ET)

Nov 28, 2018 · 5:09 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001581720

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Nov 26, 2018	M	1,250	$11.35	A	1,250	D
Common Stock^F2,F3	Nov 26, 2018	S	500	$151.57	D	750	D
Common Stock^F2,F4	Nov 26, 2018	S	250	$152.39	D	500	D
Common Stock	Nov 26, 2018	S	100	$153.30	D	400	D
Common Stock^F2,F5	Nov 26, 2018	S	300	$155.13	D	100	D
Common Stock	Nov 26, 2018	S	100	$156.04	D	0	D
Common Stock	Nov 27, 2018	M	1,250	$11.35	A	1,250	D
Common Stock^F2,F6	Nov 27, 2018	S	200	$137.89	D	1,050	D
Common Stock^F2,F7	Nov 27, 2018	S	350	$138.95	D	700	D
Common Stock^F2,F8	Nov 27, 2018	S	200	$140.94	D	500	D
Common Stock^F2,F9	Nov 27, 2018	S	200	$143.84	D	300	D
Common Stock	Nov 27, 2018	S	100	$147.09	D	200	D
Common Stock^F2,F10	Nov 27, 2018	S	100	$148.20	D	100	D
Common Stock	Nov 27, 2018	S	100	$151.55	D	0	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F11	$11.35	Nov 26, 2018	M	1,250	D	—	Apr 30, 2025	Common Stock	1,250	21,250	D
Employee Stock Option (Right to Buy)^F11	$11.35	Nov 27, 2018	M	1,250	D	—	Apr 30, 2025	Common Stock	1,250	20,000	D

Explanation of responses

F1The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
F10The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.13 to $148.24 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the one-year anniversary of the Reporting Person's employment commencement date, and thereafter vests as to 1/48th of the shares in equal monthly installments.
F2Represents the aggregate of sales effected on the same day at different prices.
F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.09 to $152.08 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.21 to $152.61 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.69 to $155.37. per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.63 to $138.15 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.68 to $139.10 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.64 to $141.24 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.54 to $144.14 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.